Portal de investigação
Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial
Autores da FMUP
Participantes de fora da FMUP
- Peyrin-Biroulet, L
- Vermeire, S
- D'Haens, GR
- Panés, J
- Dignass, A
- Le Bars, M
- Lahaye, M
- Nazar, M
- Ni, L
- Bravatà, I
- Lavie, F
- Daperno, M
- Lukás, M
- Armuzzi, A
- Löwenberg, M
- Gaya, DR
- Danese, S
- STARDUST
Unidades de investigação
Abstract
Abstract no disponible
Filiações
Filiações não disponíveis
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Peyrin,L,Vermeire,S,D'Haens,GR,Panés,J,Dignass,A,Magro,F,Le,M et al. Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND:Oxford University Press. 2022 p.p. 132-134.
